Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”
Therapeutic Advances in Gastroenterology · 2026-07 · 19
DOI: 10.1177/17562848261465254 ↗Kurz gefasst
Leserbrief in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 02.07.2026. Verfasst von Aliza Altaf und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Medicine, Peoples University of Medical and Health Science for Women, Nawabshah, Sindh 67450, Pakistan. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
inflammation. With mucosal healing becoming an important therapeutic goal in current management of inflammatory bowel disease, sole dependence on clinical response may overestimate the actual effectiveness of high-dose upadacitinib. A more detailed discussion of this discordance would have improved interpretation of the study findings and provided better insight into the long-term disease-modifying potential of high-dose maintenance therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departement of Medicine, Peoples University of Medical and Health Science for Women, Nawabshah, Sindh 67450, Pakistan.
- Departement of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan.
ORCID-Profile: Aliza Altaf, Fiza Memon
Zitieren
APA
Altaf, A., Memon, F., & Kumar, L. (2026). Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”. Therapeutic Advances in Gastroenterology, 19. https://doi.org/10.1177/17562848261465254
Vancouver
Altaf A, Memon F, Kumar L. Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”. Therapeutic Advances in Gastroenterology. 2026;19. doi:10.1177/17562848261465254
BibTeX
@article{Altaf2026,
author = {Altaf, Aliza and Memon, Fiza and Kumar, Lavish},
title = {Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”},
journal = {Therapeutic Advances in Gastroenterology},
year = {2026},
volume = {19},
doi = {10.1177/17562848261465254}
}
EUVIMED